Featured Research

from universities, journals, and other organizations

Aggressive blood cancers: Response of multiple myeloma patients to Carfilzomib after other treatments have failed

Date:
December 7, 2010
Source:
John Theurer Cancer Center
Summary:
A new proteasome inhibitor may hold hope for patients with multiple myeloma who have been treated unsuccessfully with other drugs. The medication has already demonstrated antitumor activity in phase 1 and 2 studies in patients with relapsed or refractory myeloma.

A new proteasome inhibitor may hold hope for patients with multiple myeloma who have been treated unsuccessfully with other drugs. Dr. Siegel and colleagues conducted an open-label single-arm phase 2b study of carfilzomib, a novel drug in development for treating multiple myeloma. The medication has already demonstrated antitumor activity in phase 1 and 2 studies in patients with relapsed or refractory myeloma.

The current study enrolled 266 patients (257 of whom could be evaluated), who had myeloma for a median of 5.4 years. Patients in the study must have received at least two prior treatments with other medications or stem cell transplantation, with a median pre-study rate of five prior courses of treatment. Eighty-three percent had disease that progressed within 60 days of their last previous treatment, and 17 percent had achieved less than a 25 percent response to their treatment regimen that immediately preceded the study. Patients received the carfilzomib in increasing doses for up to 12 treatments, and some also entered an extension study.

Thirty-six percent of study participants responded to carfilzomib, with a median response duration of 6.3 months in those with some response.

"This study demonstrates that carfilzomib has the potential to offer substantial clinical benefit to patients with relapsed or refractory myeloma," said Dr. Siegel. "We did not see cumulative side effects, indicating the medication may be appropriate for prolonged single-agent dosing for chronic disease."

This research was presented at the annual meeting of the American Society of Hematology (ASH) taking place December 4-7, 2010 in Orlando, Florida.


Story Source:

The above story is based on materials provided by John Theurer Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

John Theurer Cancer Center. "Aggressive blood cancers: Response of multiple myeloma patients to Carfilzomib after other treatments have failed." ScienceDaily. ScienceDaily, 7 December 2010. <www.sciencedaily.com/releases/2010/12/101207130007.htm>.
John Theurer Cancer Center. (2010, December 7). Aggressive blood cancers: Response of multiple myeloma patients to Carfilzomib after other treatments have failed. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2010/12/101207130007.htm
John Theurer Cancer Center. "Aggressive blood cancers: Response of multiple myeloma patients to Carfilzomib after other treatments have failed." ScienceDaily. www.sciencedaily.com/releases/2010/12/101207130007.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins